After acne improves: what continuing skincare can and cannot promise

After acne improves, gentle skincare continues to support hydration, comfort and sun protection. A manageable routine can also help patients tolerate any continuing acne medicine. Selected medicines and acne-targeted skincare formulations have maintenance evidence, but they serve different purposes and should be considered individually.^{1, 2, 3, 4, 7}

The next step is to agree what should continue, why it is being used and when to review it. Some patients benefit from maintenance medication, particularly after previous recurrence; others do not need it. Daily supportive care can remain useful in either situation.⁵

Key messages

• Continue gentle, tolerated skincare for comfort and protection after acne treatment.^{1, 2, 8}

• Distinguish supportive care, acne-targeted cosmetics and maintenance medicines before interpreting a maintenance claim.^{1, 6, 7}

• Controlled trials support defined maintenance outcomes for selected medicines; skincare findings remain specific to the tested formulation and regimen.^{3, 4, 7, 13}

• Review tolerability, actual product use, pregnancy considerations and any returning lesions as part of an individual plan.^{5, 6, 17, 18}

What does maintenance mean after acne improves?

Maintenance describes the aim of preserving improvement after an initial treatment phase. In practice, patients may use the term for daily skincare, an acne-targeted cosmetic or a continuing medicine. Establish which is meant before discussing benefit.

These roles can coexist, but they do not share one evidence base. Non-prescription status also does not identify a cosmetic: the American Academy of Dermatology (AAD) lists adapalene as an acne-treatment retinoid available without prescription in the United States. The UK National Institute for Health and Care Excellence (NICE) advises that maintenance medication is not always needed after acne clears.^{5, 6, 7}

What should a continuing daily routine include?

Keep daily care simple: gentle cleansing, a suitable moisturiser and appropriate sun protection. A 2023 expert publication on acne and the skin barrier recommends ongoing fragrance-free, non-comedogenic care, including after prescription treatment stops.¹

The AAD advises gentle washing with a non-abrasive cleanser, using fingertips rather than scrubbing tools, up to twice daily and after sweating. Avoid intensifying washing or adding unnecessary exfoliants when the skin is irritated. Apply moisturiser when the skin feels dry; using it after washing while some moisture remains can help retain water.^{2, 8}

Selected adjunctive-care studies support comfort benefits. In a 12-week randomised study during acne medication, a ceramide-containing cleanser and moisturiser routine received better patient ratings for dryness, tightness and comfort than the control routine. It tested a complete regimen, rather than the isolated ingredient or relapse prevention.⁹

The L’Oréal Dermatological Beauty Pro resource on ceramide-containing moisturisers alongside acne treatment provides related supportive-care context. Its purpose here is to help explain comfort and tolerability, not to establish independent prevention of recurrence.

Sun protection addresses exposure and pigmentation. Outdoors, AAD advice includes shade, protective clothing and broad-spectrum, water-resistant sunscreen with sun protection factor (SPF) 30 or higher. When post-inflammatory hyperpigmentation, or dark marks after inflammation, is a concern, tinted sunscreen containing iron oxides can also provide visible-light protection.^{8, 11}

Avoid picking, popping or squeezing returning lesions, which can delay clearing and increase scarring and dark-mark risk. These habits remain useful whether or not a maintenance medicine is prescribed.⁸

Who may benefit from continuing an acne medicine?

Topical retinoids act on follicular cells to reduce excessive cornification and blockage, including the microcomedone, the microscopic precursor of a visible comedone. This provides a biological rationale for maintenance in selected patients. Benzoyl peroxide reduces acne-associated bacteria and can be combined with another acne medicine.^{6, 12}

NICE identifies previous recurrence after treatment as a reason to consider maintenance. Its rationale discusses adapalene/benzoyl peroxide and, when that combination is unsuitable or not tolerated, adapalene, azelaic acid or benzoyl peroxide. These are guideline-context options rather than interchangeable treatments with identical evidence.⁵

Review previous severity and scarring, what produced improvement, current activity, tolerability, preferences and the feasibility of continued use. Evidence for a studied adapalene medicine does not transfer to cosmetic retinol or an ordinary moisturiser. The patient’s actual formulation and instructions should guide the plan.^{3, 4, 5, 6}

What have controlled maintenance trials measured?

A maintenance study needs a defined starting point, comparator and outcome. The two trials below evaluated active medicines in particular post-treatment populations, rather than an ordinary skincare routine.

Scroll horizontally to view the full table.

A 2016 systematic review identified five randomised trials and three non-randomised studies. Adapalene and adapalene/benzoyl peroxide favoured active treatment for specified lesion-count outcomes. Results varied by endpoint: two of three adapalene trials did not show significant differences for certain global or clear/almost-clear outcomes. The authors highlighted the small evidence base.¹³

These trials support selected medication decisions. Their different success definitions and populations mean the percentages should not be pooled into one probability of remaining acne-free, or quoted as a result for supportive skincare.^{3, 4, 13}

What evidence supports acne-targeted skincare after treatment?

A 2025 expert consensus on dermocosmetics in acne reviewed controlled studies in which particular formulations maintained clearance or sustained reductions in visible lesions after medical therapy. It rated the overall dermocosmetic evidence low to moderate. This supports considering the tested products in their original setting, rather than a universal maintenance effect for all skincare.⁷

The Nordic expert algorithm integrating skincare in acne care also acknowledges that different agents and endpoints make general conclusions difficult. When checking a claim, identify the formula, preceding treatment, any continuing medicine, comparator, outcome and follow-up.¹⁴

Combined medication and skincare regimens do not isolate a moisturiser effect. Similarly, an uncontrolled 12-month study after isotretinoin cannot separate a later product’s contribution from the lasting treatment effect and other influences. A basic cleanser, moisturiser and sunscreen can still be worthwhile for comfort and protection without a generic relapse-prevention percentage.^{2, 7}

How can ongoing treatment remain tolerable and safe?

Agree when the treatment should be reviewed, rather than leaving it to continue indefinitely. NICE’s rationale supports a maintenance review at 12 weeks to decide whether treatment remains necessary. That is a decision point, not a universal stopping rule; the length of a trial is not an instruction for every patient.⁵

Different medicines have different continuing roles. A topical retinoid may remain appropriate, while systemic antibiotic exposure should be limited. AAD guidance recommends combining systemic antibiotics with benzoyl peroxide and other topical therapies. Review any antibiotic-containing regimen explicitly; supportive skincare does not itself establish prevention of resistance or remove the need for stewardship.^{6, 15, 16}

Ask about dryness, stinging, peeling and all non-prescription actives. For retinoid irritation, the treating clinician may adjust the amount or frequency or advise a change in moisturiser placement. Follow the specific medicine and agreed plan rather than a generic intermittent schedule.^{6, 17}

Pregnancy and plans to conceive belong in relevant medication reviews, even when skin looks clear. Topical retinoids are contraindicated during pregnancy. People who are pregnant or trying to conceive should obtain clinical advice before treating acne themselves, including with non-prescription products.^{17, 18}

What needs review after oral isotretinoin?

The Nordic expert algorithm recommends moisturisers to support tolerability during isotretinoin and skincare as part of maintenance afterwards. These are supportive-care recommendations, not a demonstrated generic relapse-prevention effect.¹⁴

At the end of treatment, review dryness, current lesions and the completed regimen with the prescribing team. The AAD describes treatment-related dryness as clearing after isotretinoin stops, but provides no universal calendar for restarting topical actives. Decide which products, if any, should be introduced rather than automatically restarting everything used previously.¹⁹

If acne returns, reassess current severity and treatment history. NICE’s relapse rationale uses these factors to guide the next step after isotretinoin. Recurrence is an active disease question, rather than evidence that the person needed a more elaborate skincare routine.⁵

What should a reviewable long-term plan record?

Record what produced improvement, how long the skin has been clear, previous recurrence, current medicines and skincare, tolerability and the patient’s priorities. Separate the daily care that supports comfort from any medicine intended to control new lesions.^{5, 6}

• Daily supportive care: which cleanser, moisturiser and sun protection can be used comfortably.

• Active treatment: whether a medicine continues, why, and its prescribed instructions.

• Progress: new lesions, symptoms, actual use and the patient’s main concerns.

• Review: when to reassess, who will advise on medicine changes and what should prompt earlier contact.

Deep, painful or newly scarring lesions and persistent breakouts need clinical assessment. Distinguish new active acne from flat residual redness or pigment and from depressed or raised structural scars. Some retinoids can improve dark spots, but remaining marks do not automatically call for more acne medication.^{6, 8, 18, 20}

The goal is a sustainable plan with a clear purpose for each step. The L’Oréal Dermatological Beauty Pro resource on day-to-day care for acne can support that conversation. Continued skincare can be useful even when no maintenance medicine is needed and no routine can guarantee that acne will never return.

References

1. Schachner LA, Alexis AF, Andriessen A, et al. Insights into acne and the skin barrier: Optimizing treatment regimens with ceramide-containing skincare. J Cosmet Dermatol. 2023;22(11):2902–2909. doi:10.1111/jocd.15946. View source ↗
2. American Academy of Dermatology. Moisturizer: Why you may need it if you have acne [Internet]. Accessed 3 November 2026. View source ↗
3. pubmed.ncbi.nlm.nih.gov. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial [Internet]. Accessed 3 November 2026. View source ↗
4. pubmed.ncbi.nlm.nih.gov. Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24 weeks and assessment of atrophic acne scars using three-dimensional image analysis [Internet]. Accessed 3 November 2026. View source ↗
5. National Institute for Health and Care Excellence. Rationale and impact [Internet]. Accessed 3 November 2026. View source ↗
6. American Academy of Dermatology. Acne: Diagnosis and treatment [Internet]. Accessed 3 November 2026. View source ↗
7. Thiboutot D et al. International expert consensus recommendations for the use of dermocosmetics in acne. Journal of the European Academy of Dermatology and Venereology. 2025. View source ↗
8. American Academy of Dermatology. Acne: Tips for managing [Internet]. Accessed 3 November 2026. View source ↗
9. Draelos ZD, Baalbaki N, Colon G, Dreno B. Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment. Journal of Drugs in Dermatology. 2023. View source ↗
10. Lain E, Andriessen AE. Choosing the Right Partner: Complementing Prescription Acne Medication With Over-the-Counter Cleansers and Moisturizers. Journal of Drugs in Dermatology. 2020. View source ↗
11. American Academy of Dermatology. How to fade dark spots in darker skin tones [Internet]. Accessed 3 November 2026. View source ↗
12. pmc.ncbi.nlm.nih.gov. Management of acne [Internet]. Accessed 3 November 2026. View source ↗
13. pubmed.ncbi.nlm.nih.gov. How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy [Internet]. Accessed 3 November 2026. View source ↗
14. Bjerring P, Anckar O, Andriessen A, Kyrklund C, Layton A, Nordal ABT, Oprica C. NECASA I: A Practical Algorithm Integrating Skincare in the Management of Acne Patients in the Nordic European Countries. Journal of Drugs in Dermatology. 2024. View source ↗
15. American Academy of Dermatology. Acne clinical guideline [Internet]. Accessed 3 November 2026. View source ↗
16. Dreno B, Dekio I, Baldwin H, Demessant AL, Dagnelie MA, Khammari A, Corvec S. Acne microbiome: From phyla to phylotypes. Journal of the European Academy of Dermatology and Venereology. 2024;38(4):657-664. View source ↗
17. pmc.ncbi.nlm.nih.gov. Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice [Internet]. Accessed 3 November 2026. View source ↗
18. American Academy of Dermatology. Adult acne treatment dermatologists recommend [Internet]. Accessed 3 November 2026. View source ↗
19. American Academy of Dermatology. Isotretinoin: The truth about safety, side effects, and skin care [Internet]. Accessed 3 November 2026. View source ↗
20. Baldwin HE, Ablon G, Callender V, et al. Challenges in Adult Acne and the Role of Skin Care in Managing the Condition. J Drugs Dermatol. 2024;23(8):674–679. doi:10.36849/JDD.8471. View source ↗